Resources & Guides

A pharmacokinetics-anchored look at microdosing GLP-1 side effects across semaglutide, tirzepatide, and retatrutide: what trial dose-response data tells us about lower-dose GI tolerability, and which class-level serious risks persist at every dose.

While retatrutide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.

A community synthesis of what Reddit threads actually report about GLP-1 microdosing: fewer side effects, the "just 10 lbs" cohort, off-label inflammation use, and where anecdote meets pharmacokinetics. Anecdotes, not medical advice.

A practical how-to guide for running a GLP-1 microdosing protocol across semaglutide, tirzepatide, and retatrutide. Covers approach selection, compound-specific steps, titration decisions, and calculator modeling.

What microdosing GLP-1 actually means, how it differs from standard titration, what clinical evidence exists, and the risks of using sub-standard doses of semaglutide, tirzepatide, or retatrutide.

Everything you need to know about microdosing GLP-1 agonists. Split dosing protocols for retatrutide, tirzepatide, and semaglutide to reduce side effects without sacrificing weight loss results.

While semaglutide is designed for weekly dosing, its 7-day half-life makes it uniquely suited for split dosing exploration. We examine the pharmacokinetics, protocols, and considerations for microdosing Ozempic and Wegovy.

While tirzepatide is designed for weekly dosing, emerging interest in microdosing raises questions about splitting doses to optimize tolerability and efficacy. We examine the science, community experiences, and critical considerations.